Results from the US Clinical Trial of PNEUMOSTEM for Treating Lung Disease is Published in International Journal2019/05/13STEM CELL THERAPEUTIC
MEDIPOST, ends phase I and II clinical trials with PNEUMOSTEM, the effective treatment of BPD for preterm infants2019/01/08STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US2016/06/30STEM CELL THERAPEUTIC
MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease2016/05/03STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in Canada for its ‘PNEUMOSTEM’ Used to Treat Lung Diseases2016/03/10STEM CELL THERAPEUTIC
‘PNEUMOSTEM’ selected as the ‘Newly developed and promising medical technology’ by National evidence based healthcare collaborating agency2015/11/02STEM CELL THERAPEUTIC
MEDIPOST announced extension plans in US ’2015 Stem Cell Meeting on the Mesa’2015/10/07STEM CELL THERAPEUTIC
Lung disease medicine, ‘PNEUMOSTEM’ was designated as ‘Orphan Drug’ in Europe2015/07/06STEM CELL THERAPEUTIC
The only Korean company invited to North American Rare Medicine conference2015/04/24STEM CELL THERAPEUTIC
Administration of lung disease medicine ‘PNEUMOSTEM’ in clinical trial completed2015/04/15STEM CELL THERAPEUTIC
MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®2023/12/27
MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billion, to be Used for Global Market Expansion Including the U.S.2023/10/04
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal2023/05/02
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan2023/01/16
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01